AgomAb Therapeutics NV Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2019	FY 2018
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Net Income	-56.88	-46.27	-11.39	-8.14	-	-
Depreciation & Amortization	0.39	0.31	0.1	0.02	-	-
Stock-Based Compensation	4.43	1.07	2.16	2.21	-	-
Other Operating Activities	3.64	-0.66	-19.58	-14.47	-	-
Change in Accounts Payable	-1.79	-0.23	3.69	2.95	-	-
Change in Unearned Revenue	0.77	-0.4	-0.58	1.45	-	-
Change in Other Net Operating Assets	-1.57	-0.66	1.01	-2.99	-	-
Operating Cash Flow	-51.01	-46.83	-24.59	-18.97	-	-
Capital Expenditures	-0.36	-0.68	-	-	-	-
Cash Acquisitions	-3	-	-	-4.59	-	-
Investment in Securities	-	-	40	-40	-	-
Investing Cash Flow	-3.36	-0.68	40	-44.59	-	-
Long-Term Debt Issued	-	-	-	0.14	-	-
Long-Term Debt Repaid	-	-0.16	-0.1	-0.72	-	-
Net Debt Issued (Repaid)	-0.37	-0.16	-0.1	-0.58	-	-
Issuance of Common Stock	82.06	97.06	79.87	38.39	-	-
Other Financing Activities	-0.13	-0.13	-0.45	-0.17	-	-
Financing Cash Flow	81.56	96.76	79.32	37.63	-	-
Foreign Exchange Rate Adjustments	-0.2	-0.2	-	-	-	-
Miscellaneous Cash Flow Adjustments	0	0	-	-	-	-
Net Cash Flow	26.99	49.06	94.73	-25.92	-	-
Free Cash Flow	-51.37	-47.5	-24.59	-18.97	-	-
Free Cash Flow Per Share	-2054.80	-1900.12	-983.68	-758.68	-	-
Cash Interest Paid	0.01	0.01	0.02	0.04	-	-
Cash Income Tax Paid	0	0	0	0	-	-
Levered Free Cash Flow	-	-16.51	-49.9	-	-	-
Unlevered Free Cash Flow	-	-16.47	-49.88	-	-	-
Change in Working Capital	-2.59	-1.28	4.12	1.41	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q